Various steps have been taken by Government of India to address the emerging issues for effective management of the recent unprecendented spike in COVID19 cases across various States and UTs. These pro-active measures taken by the Union Government under a ‘whole of government’ are also being regularly reviewed and monitored at the highest level.
The escalation of serious COVID19 patients in hospitals for effective clinical management has also resulted in anincrease in the demand of Remdesivir.
Keeping in mind the sudden surge in demand in the country for Remdesivir Injection required for Covid-19 therapy, the manufacturing capacity of domestic Remdesivir manufacturers has been ramped up.
The production capacity is being ramped up from current level of 38 lakh vials per month to 74 lakh vials per month, and 20 additional manufacturing sites have been approved. Export of Remdesivir has also been prohibited on 11th April,2021 in order to shore up domestic supplies.
Remdesivir being an investigational therapy drug given in acute and severe versions of COVID-19 where oxygen support is a must, this allocation pertains to 14 States to which medical oxygen is allocated and 5 other states where the high volume of supplies are being observed.
